Name: Latest research reports of Ajanta Pharma Ltd. authored by BOB Capital Markets Ltd. and published by - Trendlyne research reports.
Item: Ajanta Pharma Ltd.
Rating: 5
Author: BOB Capital Markets Ltd.

Ajanta Pharma Ltd.

NSE: AJANTPHARM | BSE: 532331 | ISIN: INE031B01049 | Industry: Pharmaceuticals
| Expensive Performer

2576.8500 38.60 (1.52%)

NSE Mar 17, 2025 15:31 PM

26.06% Fall from 52W High

Volume: 93,024

Ajanta Pharma Ltd.

28 Jul 2023

2576.85

1.52%

Ajanta Pharma (BUY): Q1 beat sparked by sharp margin recovery

Buy: Ajanta Pharma Ltd.

Target

BOB Capital Markets Ltd.

Strong Q1 beat with EBITDA/PAT of Rs 2.7bn/Rs 2.1bn coming in 17%/ 39% ahead of consensus due to margin recovery

Ajanta Pharma Ltd. is trading below all available SMAs